Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
Date:8/2/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 2, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced financial results for its second quarter and six months ended June 30, 2012 and provided an overview of the clinical development activities of its two product candidates, custirsen and OGX-427.

Custirsen Clinical Development Highlights

  • The Company announced detailed plans for the ENSPIRIT trial, an international, randomized Phase 3 study in approximately 1,100 patients with advanced or metastatic non-small cell lung cancer (NSCLC). The trial will evaluate the potential survival benefit of combining custirsen with docetaxel as a second-line treatment in patients who have progressed after initial chemotherapy treatment has failed. Enrollment is planned to begin later this year and the trial will be managed by our development partner for custirsen, Teva Pharmaceuticals Industries LTD (TEVA).
  • Custirsen's primary registration Phase 3 study, SYNERGY, evaluating a survival benefit for custirsen plus first-line chemotherapy in patients with castrate-resistant prostate cancer (CRPC), remains on schedule and patient accrual is expected to be completed in the second half of 2012.
  • The Phase 3 AFFINITY study, evaluating a survival benefit for custirsen in combination with Jevtana® (cabazitaxel) as second-line chemotherapy in patients with CPRC, is expected to begin patient enrollment in the near future.
  • OGX-427 Clinical Development Highlights

  • Preliminary data from an investigator-sponsored Phase 2 clinical trial of OGX-427 in chemotherapy-naive patients with metastatic CRPC were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2012. Preliminary study results showed a higher number of patients without disease progression at 12 weeks and greater declines in prostate
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
    6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
    8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
    9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
    10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
    11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/28/2015)... PLEASANTON, Calif. , April 28, 2015  Clinicians ... Boise, Idaho , will demonstrate that Leaf Healthcare,s ... with a caregiver,s pressure ulcer prevention turn protocols. Their ... Wound Care in San Antonio, Texas ... will present a poster entitled "Optimizing patient turning resources ...
    (Date:4/28/2015)... April 28, 2015 Exagen Diagnostics, Inc., ... significant unmet need for the accurate diagnosis and ... announced today that its Avise SLE+ Connective Tissue ... orders since launch, and that adoption continues to ... identifying Connective Tissue Disease (CTD), including, but not ...
    (Date:4/28/2015)... 2015 New and more complex medicines ... of manufacturers, payers, pharmacists and patients. Now ... premiere journal, is partnering with the National Association ... association dedicated solely to this developing field, to ... this growing need. "This partnership provides ...
    Breaking Medicine Technology:VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 2VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 3VA Presentation at Wound Symposium to Show New Wireless Patient Monitoring System Improves Pressure Ulcer Turn Compliance 4Exagen Sees Growing Adoption of Avise Diagnostic for Connective Tissue Disease with New Milestone 2Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 2Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 3Specialty Pharmacy Times Partners With National Association of Specialty Pharmacy to Improve Care for Patients 4
    ... The nationwide launch of the Recovery Audit Contractor (RAC) program ... sizes and types are busy preparing for it as not ... findings resulting in money owed to Medicare. Think adding staff ... with mountains of new work. Designed based on the experiences ...
    ... Bionovo Inc. (Nasdaq: BNVI ) announced today the ... effect of tamoxifen on estrogen receptor beta (ERb) gene ... published in Molecular and Cellular Endocrinology, demonstrate that tamoxifen ... of breast cancer cell proliferation. , "Tamoxifen has ...
    Cached Medicine Technology:American Hospital Association (AHA) Names OnBase 'RACTrac Compatible' 2American Hospital Association (AHA) Names OnBase 'RACTrac Compatible' 3Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 2Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta 3
    (Date:4/28/2015)... PA (PRWEB) April 28, 2015 Helping ... decision-making process when a loved one dies can be ... the funeral arrangements and final tribute can ... families in need, Beinhauer Family Funeral Homes ... services offered to families by doubling its number of ...
    (Date:4/28/2015)... 28, 2015 Two leaders in patient ... to Becker's Hospital Review’s list of 50 Experts ... Pronovost, M.D., Ph.D. , director of the Armstrong ... vice president for patient safety and quality at Johns ... vice president of medical affairs and chief patient safety ...
    (Date:4/28/2015)... Georgia State University’s School of Public ... will partner with the school on efforts to improve ... that produces more tobacco and has more smokers than ... Tobacco Control Partnership-Tobacco Free Cities, will focus on a ... support tobacco control efforts and where public health organizations ...
    (Date:4/28/2015)... 2015 Vancouver personal injury lawyers at ... it is smarter to call an attorney before calling ... The blog reasons that there are several benefits of ... well-versed with the law and can help clients reach ... to on their own. Competent and experienced personal injury ...
    (Date:4/28/2015)... 28, 2015 The biologics safety testing ... drivers for the market include growth of the pharmaceutical ... drug launches. Over the years, the number of drug ... and 2010, the FDA approved 225 drug applications and ... Europe accounted for 3,822 of the pharmaceutical and 1,998 ...
    Breaking Medicine News(10 mins):Health News:Beinhauer's Increasing Number of Celebrants to Meet Growing Demand for Personalized Funeral Ceremonies 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Georgia State Names Partner Cities For Tobacco Control Project 2Health News:Vancouver Personal Injury Lawyers Recently Stated in Latest Blog That It Is Smarter To Call A Lawyer Before ICBC 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 2Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 3Health News:Biological Safety Testing Market, By Application Product & Test – Global Forecast 2019 - Report Released by MarketsandMarkets 4
    ... STAMFORD, Conn., Aug. 27 American children miss more ... other two diseases combined.(1) As parents help their kids prepare for ... a lifetime of good oral health with the new Philips Sonicare ... Sonicare For Kids is specially designed to support kids, needs at ...
    ... , DES PLAINES, Ill. and NEW ... into an agreement with Pfizer Inc to develop a molecular diagnostic ... the presence of gene rearrangements. Pfizer has developed a novel ... of many cancers. To be eligible to receive Pfizer,s oral ...
    ... those with deceased donor transplant organs, study shows , ... disease may do just as well receiving treatment at ... donor, new research has found. , Researchers in Canada ... had either received a kidney transplant from a deceased ...
    ... , , , ... and CHATTANOOGA, Tenn., Aug. 27 Sandata Technologies, Inc., a ... healthcare and social services communities, and Volunteer State Health Plan ... announced an agreement by which VSHP will use Sandata,s IntegriCare ...
    ... China, Aug. 27 /PRNewswire-Asia/ -- On August 10, 2009, Winner,Medical ... entered into a contract with a machine producer in China ... This new machineries will constitute the ... operated in the Company,s,subsidiary in Huanggang, and it is expected ...
    ... , , CUPERTINO, Calif., ... today reported that it has signed an exclusive long term ... Inc. (NYSE: KG ). This agreement stipulates the ... based on DURECT,s manufacturing cost plus a specified percentage mark-up, ...
    Cached Medicine News:Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 2Health News:Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 2Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 3Health News:Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Sandata Selected by Volunteer State Health Plan to Manage TennCare Choices 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 2Health News:Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 2Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 3Health News:DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R) 4
    ... Stylish and comfortable eye protection Properly ... 90% of scatter radiation. Our high quality ... and comfort with minimized weight. Our lenses ... optics that meet all industry standards. Most ...
    ... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
    ... lenses and frames are designed with the safety ... lenses are Schott RS-520 (also called SF-6) leaded ... These lenses meet standards, as set for optical ... ,While our eyewear is protecting your eyes, ...
    ... and frames are designed with the safety and ... are Schott RS-520 (also called SF-6) leaded glass, ... lenses meet standards, as set for optical clarity, ... ,While our eyewear is protecting your eyes, it ...
    Medicine Products: